Differences in HDL-Bound Apolipoproteins in Patients With Advanced Liver Fibrosis Due to Nonalcoholic Fatty Liver Disease

• Published in: The journal of clinical endocrinology and metabolism 2023-01, Vol.108 (1), p.42-51
• Main Authors: Bril, Fernando, Pearce, Ryan W, Collier, Timothy S, McPhaul, Michael J
• Format: Article
• Language: English
• Subjects: Analysis and chemistry; Apolipoproteins; Apolipoproteins C; Biopsy; Blood; Cardiac patients; Cardiovascular Diseases - pathology; Clinical; Coronary heart disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - complications; Fatty liver; Fibrosis; Health aspects; Humans; Lipoproteins; Liver - pathology; Liver cirrhosis; Liver Cirrhosis - pathology; Mass spectrometry; Medical research; Medicine, Experimental; Mortality; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - pathology; Nuclear magnetic resonance spectroscopy; Protein binding; Triglycerides; Type 2 diabetes
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/clinem/dgac565

The mechanisms leading to increased cardiovascular disease in patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis remain incompletely understood. This study assessed HDL-bound proteins in patients with NAFLD with or without advanced fibrosis. This cross-sectional study at a university hospital included 185 patients with or without type 2 diabetes (T2D). Patients underwent liver proton magnetic resonance spectroscopy to measure intrahepatic triglyceride accumulation and those with NAFLD underwent a percutaneous liver biopsy. Advanced lipid testing with lipoprotein subfraction measurements and targeted proteomics of HDL-bound proteins was performed. Patients with and without advanced fibrosis had similar clinical characteristics, except for lower HDL-C (34 ± 8 vs 38 ± 9 mg/dL, P = 0.024) and higher prevalence of T2D in advanced fibrosis. Patients with advanced fibrosis had lower HDL particle number. A panel of 28 HDL-bound proteins were targeted and quantified by multiple reaction monitoring liquid chromatography-tandem mass spectrometry. Five proteins were found to be decreased in patients with advanced fibrosis (ApoC-I [P < 0.001], ApoC-IV [P = 0.012], ApoM [P = 0.008], LCAT [P = 0.014], and SAA4 [P = 0.016]). No differences were observed in these proteins in patients with vs without NAFLD or steatohepatitis. The pCAD index, associated with coronary artery disease and cardiovascular mortality, was significantly higher in patients with advanced fibrosis (97 ± 5 vs 86 ± 25, P = 0.04). Patients with NAFLD with advanced fibrosis showed significant differences in HDL-bound protein levels; this translated into increased cardiovascular risk based on pCAD index. Different lipoprotein composition and function may explain the link between liver disease and increased cardiovascular mortality in these patients.